Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes

Circulation: Genomic and Precision Medicine

Volumn 12, Issue 2, 2019, Pages 57-64

  Ingles, Jodie ^a,b   Goldstein, Jennifer ^c   Thaxton, Courtney ^c   Caleshu, Colleen ^d   Corty, Edward W ^c   Crowley, Stephanie B ^c   Dougherty, Kristen ^e   Harrison, Steven M ^f   McGlaughon, Jennifer ^c   Milko, Laura V ^c   Morales, Ana ^g   Seifert, Bryce A ^c   Strande, Natasha ^c   Thomson, Kate ⁱ   Peter Van Tintelen, J ^j   Wallace, Kathleen ^c   Walsh, Roddy ^k,l   Wells, Quinn ^m   Whiffin, Nicola ^k,l   Witkowski, Leora ⁿ   Semsarian, Christopher ^a,b   Ware, James S ^k,l   Hershberger, Ray E ^g,h   Funke, Birgit ⁿ   more..

^a University of Sydney   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ Oxford Medical Genetics Laboratory   (United Kingdom)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^l ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^m VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

genetic testing; heart failure; syndrome; uncertainty

Indexed keywords

FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; PHENOTYPE;

CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PHENOTYPE;

EID: 85061855740     PISSN: None     EISSN: 25748300     Source Type: Journal    
DOI: 10.1161/CIRCGEN.119.002460     Document Type: Article

References (31)

1. Gersh BJ, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212-e260. doi: 10.1016/j.jacc.2011.06.011
2. Elliott PM, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733-2779.
3. Semsarian C, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249-1254. doi: 10.1016/j.jacc.2015.01.019
4. Maron BJ, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785-789.
5. Jarcho JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. 1989;321:1372-1378. doi: 10.1056/NEJM198911163212005
6. Maron BJ, et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64:83-99. doi: 10.1016/j.jacc.2014.05.003
7. Cirino AL, et al. Role of genetic testing in inherited cardiovascular disease: a review. JAMA Cardiol. 2017;2:1153-1160. doi: 10.1001/jamacardio.2017.2352
8. Hershberger RE, et al; ACMG Professional Practice and Guidelines Committee. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20:899-909. doi: 10.1038/s41436-018-0039-z
9. Manrai AK, et al. Genetic misdiagnoses and the potential for health disparities. N Engl J Med. 2016;375:655-665. doi: 10.1056/NEJMsa1507092
10. Richards S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424. doi: 10.1038/gim.2015.30
11. Kelly MA, et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel. Genet Med. 2018;20:351-359. doi: 10.1038/gim.2017.218
12. Walsh R, et al. Reassessment of Mendelian gene pathogenicity using 7, 855 cardiomyopathy cases and 60, 706 reference samples. Genet Med. 2017;19:192-203. doi: 10.1038/gim.2016.90
13. Das KJ, et al. Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. Genet Med. 2014;16:286-293.
14. Furqan A, et al. Care in specialized centers and data sharing increase agreement in hypertrophic cardiomyopathy genetic test interpretation. Circ Cardiovasc Genet. 2017;10:e001700. doi: 10.1161/CIRCGENETICS.116.001700
15. Strande NT, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource. Am J Hum Genet. 2017;100:895-906. doi: 10.1016/j.ajhg. 2017.04.015
16. Rehm HL, et al; ClinGen. ClinGen-the Clinical Genome Resource. N Engl J Med. 2015;372:2235-2242. doi: 10.1056/NEJMsr1406261
17. Landrum MJ, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44(D1):D862-D868. doi: 10.1093/nar/gkv1222
18. van der Zwaag PA, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012;14:1199-1207. doi: 10.1093/eurjhf/hfs119
19. Chiu C, et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. J Am Coll Cardiol. 2010;55:1127-1135. doi: 10.1016/j.jacc.2009.11.016
20. Girolami F, et al. Novel α-actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. Circ Cardiovasc Genet. 2014;7:741-750. doi: 10.1161/CIRCGENETICS.113.000486
21. Boczek NJ, et al. Identification and functional characterization of a novel CACNA1C-mediated cardiac disorder characterized by prolonged QT intervals with hypertrophic cardiomyopathy, congenital heart defects, and sudden cardiac death. Circ Arrhythm Electrophysiol. 2015;8:1122-1132. doi: 10.1161/CIRCEP.115.002745
22. van Spaendonck-Zwarts KY, et al. Desmin-related myopathy. Clin Genet. 2011;80:354-366. doi: 10.1111/j.1399-0004.2010.01512.x
23. Knoblauch H, et al. Contractures and hypertrophic cardiomyopathy in a novel FHL1 mutation. Ann Neurol. 2010;67:136-140. doi: 10.1002/ana.21839
24. Gomez J, et al. Screening of the Filamin C gene in a large cohort of hypertrophic cardiomyopathy patients. Circ Cardiovasc Genet. 2017;10:e001584. doi: 10.1161/CIRCGENETICS.116.001584
25. Valdés-Mas R, et al. Mutations in Filamin C cause a new form of familial hypertrophic cardiomyopathy. Nat Commun. 2014;5:5326. doi: 10.1038/ncomms6326
26. Grant AR, et al. Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework. Hum Mutat. 2018 Nov;39(11):1485-1493.
27. Almomani R, et al. Biallelic truncating mutations in ALPK3 cause severe pediatric cardiomyopathy. J Am Coll Cardiol. 2016;67:515-525. doi: 10.1016/j.jacc.2015.10.093
28. Ackerman JP, et al. The promise and peril of precision medicine: phenotyping still matters most [published online October 8, 2016]. Mayo Clin Proc. 10.1016/j.mayocp.2016.08.008
29. MacArthur DG, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508:469-476. doi: 10.1038/nature13127
30. Whiffin N, et al. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med. 2017;19:1151-1158. doi: 10.1038/gim.2017.26
31. Whiffin N, et al. CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation. Genet Med. 2018;20:1246-1254. doi: 10.1038/gim.2017.258